Progression of mild Alzheimer's disease: Knowledge and prediction models required for future treatment strategies

Alzheimer's Research and Therapy

Volumn 5, Issue 5, 2013, Pages

  Wattmo, Carina ^a   Wallin, Åsa K ^a   Minthon, Lennart ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL PRACTICE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE;

EID: 84887889652     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt210     Document Type: Article

References (57)

1. Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. LD Rosenstein, Neuropsychol Rev 1998 8 109 167 (Pubitemid 28554535)
2. Cholinesterase inhibitors for Alzheimer's disease. J Birks, Cochrane Database Syst Rev 2006 D005593
3. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. HO Tayeb, HD Yang, BH Price, FI Tarazi, Pharmacol Ther 2012 134 8 25
4. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. C Holmes, D Boche, D Wilkinson, G Yadegarfar, V Hopkins, A Bayer, RW Jones, R Bullock, S Love, JW Neal, E Zotova, JA Nicoll, Lancet 2008 372 216 223 (Pubitemid 351978111)
5. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. B Vellas, MC Carrillo, C Sampaio, HR Brashear, E Siemers, H Hampel, LS Schneider, M Weiner, R Doody, Z Khachaturian, J Cedarbaum, M Grundman, K Broich, E Giacobini, B Dubois, R Sperling, GK Wilcock, N Fox, P Scheltens, J Touchon, S Hendrix, S Andrieu, P Aisen, EU/US/CTAD Task Force Members, Alzheimers Dement 2013 9 438 444
6. Efficacy of souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. P Scheltens, JW Twisk, R Blesa, E Scarpini, CA Von Arnim, A Bongers, J Harrison, SH Swinkels, CJ Stam, H De Waal, RJ Wurtman, RL Wieggers, B Vellas, PJ Kamphuis, J Alzheimers Dis 2012 31 225 236
7. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. MA Raskind, ER Peskind, L Truyen, P Kershaw, CV Damaraju, Arch Neurol 2004 61 252 256 (Pubitemid 38197559)
8. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. T Pirttila, G Wilcock, L Truyen, CV Damaraju, Eur J Neurol 2004 11 734 741 (Pubitemid 39556753)
9. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. A Burns, S Gauthier, C Perdomo, Int J Geriatr Psychiatry 2007 22 806 812 (Pubitemid 47322609)
10. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. AK Wallin, N Andreasen, S Eriksson, S Båtsman, B Nasman, A Ekdahl, L Kilander, M Grut, M Rydén, A Wallin, M Jonsson, H Olofsson, E Londos, C Wattmo, M Eriksdotter Jonhagen, L Minthon, Swedish Alzheimer Treatment Study Group, Dement Geriatr Cogn Disord 2007 23 150 160 (Pubitemid 46333782)
11. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. C Wattmo, AK Wallin, E Londos, L Minthon, Alzheimer Dis Assoc Disord 2011 25 63 72
12. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. S Salloway, R Sperling, S Gilman, NC Fox, K Blennow, M Raskind, M Sabbagh, LS Honig, R Doody, CH Van Dyck, R Mulnard, J Barakos, KM Gregg, E Liu, I Lieberburg, D Schenk, R Black, M Grundman, Bapineuzumab 201 Clinical Trial Investigators, Neurology 2009 73 2061 2070
13. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. O Almkvist, V Jelic, K Amberla, E Hellstrom-Lindahl, L Meurling, A Nordberg, Dement Geriatr Cogn Disord 2001 12 22 32 (Pubitemid 32008938)
14. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. AS Rigaud, L Traykov, F Latour, R Couderc, F Moulin, F Forette, Pharmacogenetics 2002 12 415 420 (Pubitemid 34816421)
15. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. MF Folstein, SE Folstein, PR McHugh, J Psychiatr Res 1975 12 189 198
16. A Frances, American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Prepared by the task force on DSM-IV Washington, D.C: American Psychiatric Association 4 1994
17. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. G McKhann, D Drachman, M Folstein, R Katzman, D Price, EM Stadlan, Neurology 1984 34 939 944 (Pubitemid 14076461)
18. A new rating scale for Alzheimer's disease. WG Rosen, RC Mohs, KL Davis, Am J Psychiatry 1984 141 1356 1364
19. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. DS Knopman, MJ Knapp, SI Gracon, CS Davis, Neurology 1994 44 2315 2321
20. Assessment of older people: self-maintaining and instrumental activities of daily living. MP Lawton, EM Brody, Gerontologist 1969 9 179 186
21. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. C Wattmo, AK Wallin, E Londos, L Minthon, Gerontologist 2011 51 17 27
22. Random-effects models for longitudinal data. NM Laird, JH Ware, Biometrics 1982 38 963 974
23. Modelling mini mental state examination changes in Alzheimer's disease. MS Mendiondo, JW Ashford, RJ Kryscio, FA Schmitt, Stat Med 2000 19 1607 1616 (Pubitemid 30346250)
24. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. RG Stern, RC Mohs, M Davidson, J Schmeidler, J Silverman, E Kramer-Ginsberg, T Searcey, L Bierer, KL Davis, Am J Psychiatry 1994 151 390 396 (Pubitemid 24081459)
25. Disease progression meta-analysis model in Alzheimer's disease. K Ito, S Ahadieh, B Corrigan, J French, T Fullerton, T Tensfeldt, Alzheimers Dement 2010 6 39 53
26. Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting. AK Wallin, C Wattmo, L Minthon, Neuropsychiatr Dis Treat 2011 7 565 576
27. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial: Galantamine International-1 study group. GK Wilcock, S Lilienfeld, E Gaens, BMJ 2000 321 1445 1449
28. Maintaining cognitive function in Alzheimer disease: how effective are current treatments? PN Tariot, Alzheimer Dis Assoc Disord 2001 15 Suppl 1 26 S33
29. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. A Qaseem, V Snow, JT Cross Jr, MA Forciea, R Hopkins Jr, P Shekelle, A Adelman, D Mehr, K Schellhase, D Campos-Outcalt, P Santaguida, DK Owens, American College of Physicians/American Academy of Family Physicians Panel on Dementia, Ann Intern Med 2008 148 370 378 (Pubitemid 351665468)
30. A quick test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease. S Palmqvist, L Minthon, C Wattmo, E Londos, O Hansson, Alzheimers Res Ther 2010 2 29
31. Alzheimer's disease neuroimaging I: treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative. LS Schneider, PS Insel, MW Weiner, Arch Neurol 2011 68 58 66
32. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. RC Green, LS Schneider, DA Amato, AP Beelen, G Wilcock, EA Swabb, KH Zavitz, Tarenflurbil Phase 3 Study Group, JAMA 2009 302 2557 2564
33. Monitoring progression in Alzheimer's disease. D Galasko, J Corey-Bloom, LJ Thal, J Am Geriatr Soc 1991 39 932 941
34. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. G Alva, GT Grossberg, FA Schmitt, X Meng, JT Olin, Int J Geriatr Psychiatry 2011 26 356 363
35. Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. TB Atchison, PJ Massman, RS Doody, Arch Clin Neuropsychol 2007 22 99 107 (Pubitemid 46209595)
36. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment. JL Molinuevo, ML Berthier, L Rami, Arch Gerontol Geriatr 2011 52 18 22
37. Alzheimer's disease neuroimaging I: functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. PJ Brown, DP Devanand, X Liu, E Caccappolo, Arch Gen Psychiatry 2011 68 617 626
38. Predictors of long-term cognitive outcome in Alzheimer's disease. C Wattmo, AK Wallin, E Londos, L Minthon, Alzheimers Res Ther 2011 3 23
39. Trajectories of cognitive decline in Alzheimer's disease. PA Wilkosz, HJ Seltman, B Devlin, EA Weamer, OL Lopez, ST DeKosky, RA Sweet, Int Psychogeriatr 2010 22 281 290
40. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. D Mungas, BR Reed, WG Ellis, WJ Jagust, Arch Neurol 2001 58 1243 1247 (Pubitemid 32751743)
41. Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors. M Musicco, K Palmer, G Salamone, F Lupo, R Perri, S Mosti, G Spalletta, F Di Iulio, C Pettenati, L Cravello, C Caltagirone, J Neurol 2009 256 1288 1295
42. Predicting progression of Alzheimer's disease. RS Doody, V Pavlik, P Massman, S Rountree, E Darby, W Chan, Alzheimers Res Ther 2010 2 2
43. Cognitive decline and education in mild dementia. FW Unverzagt, SL Hui, MR Farlow, KS Hall, HC Hendrie, Neurology 1998 50 181 185 (Pubitemid 28106039)
44. Education and the course of cognitive decline in Alzheimer disease. RS Wilson, Y Li, NT Aggarwal, LL Barnes, JJ McCann, DW Gilley, DA Evans, Neurology 2004 63 1198 1202 (Pubitemid 39350017)
45. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. H Amieva, H Jacqmin-Gadda, JM Orgogozo, N Le Carret, C Helmer, L Letenneur, P Barberger-Gateau, C Fabrigoule, JF Dartigues, Brain 2005 128 1093 1101 (Pubitemid 40675464)
46. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. S Cosentino, N Scarmeas, E Helzner, MM Glymour, J Brandt, M Albert, D Blacker, Y Stern, Neurology 2008 70 1842 1849 (Pubitemid 351653957)
47. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. S Craft, L Teri, SD Edland, WA Kukull, G Schellenberg, WC McCormick, JD Bowen, EB Larson, Neurology 1998 51 149 153 (Pubitemid 28345375)
48. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. GM Murphy Jr, J Taylor, HC Kraemer, J Yesavage, JR Tinklenberg, Am J Psychiatry 1997 154 603 608 (Pubitemid 27197591)
49. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. T Kleiman, K Zdanys, B Black, T Rightmer, M Grey, K Garman, M Macavoy, J Gelernter, C Van Dyck, Dement Geriatr Cogn Disord 2006 22 73 82
50. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. BD Hoyt, PJ Massman, C Schatschneider, N Cooke, RS Doody, Arch Neurol 2005 62 454 459 (Pubitemid 40349483)
51. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E 4 non-carriers. S Salloway, R Sperling, L Honig, A Porsteinsson, M Sabbagh, E Liu, E Yuen, J Lull, M Miloslavsky, M Reichert, N Ketter, M Grundman, R Black, R Brashear, 16th Congress of the European Federation of Neurological Societies Stockholm, Sweden 2012 http://www2.kenes. com/efns/info/Documents/Salloway-Bapineuzumab%20IV%20Study%20301- EFNS%20Presentation%20Slides-9-11-2012.pdf Accessed: June 14, 2013
52. Immunotherapy against amyloid pathology in Alzheimer's disease. D Galimberti, L Ghezzi, E Scarpini, J Neurol Sci 2013 Epub ahead of print
53. An overview of longitudinal data analysis methods for neurological research. JJ Locascio, A Atri, Dement Geriatr Cogn Dis Extra 2011 1 330 357
54. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. CW Ritchie, D Ames, T Clayton, R Lai, Am J Geriatr Psychiatry 2004 12 358 369 (Pubitemid 38878856)
55. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. DS Geldmacher, G Provenzano, T McRae, V Mastey, JR Ieni, J Am Geriatr Soc 2003 51 937 944 (Pubitemid 36871141)
56. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy. C Wattmo, E Paulsson, L Minthon, E Londos, Clin Interv Aging 2013 8 329 339
57. Dose and plasma concentration of galantamine in Alzheimer's disease-clinical application. C Wattmo, E Jedenius, K Blennow, AK Wallin, Alzheimers Res Ther 2013 5 2